메뉴 건너뛰기




Volumn 24, Issue 4, 2006, Pages 432-443

Metronomic dosing of chemotherapy: Applications in pediatric oncology

Author keywords

Angiogenesis; Biomarkers; Cancer; Metronomic chemotherapy; Pediatrics

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALKYLATING AGENT; BEVACIZUMAB; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; PACLITAXEL; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE;

EID: 33745291938     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600705599     Document Type: Review
Times cited : (29)

References (128)
  • 1
    • 70450190156 scopus 로고    scopus 로고
    • Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada, Provincial/Terretorial Cancer Registries, and Health Canada. Canadian Cancer Statistics 2004.
    • Canadian Cancer Statistics 2004
  • 3
    • 33745319873 scopus 로고    scopus 로고
    • Pharmacology of cancer chemotherapy in paediatrics: Feasibility and ethical considerations in phase I trials
    • Koren, G., Diav-Citrin, O., Eds. (Bailliere Tindall, London)
    • Baruchel, S.; Rowell, M. Pharmacology of cancer chemotherapy in paediatrics: feasibility and ethical considerations in phase I trials. In Paediatric Pharmacology: Towards Evidence-Based Drug Therapy. Koren, G., Diav-Citrin, O., Eds. (Bailliere Tindall, London, 1998), 439-453.
    • (1998) Paediatric Pharmacology: Towards Evidence-Based Drug Therapy , pp. 439-453
    • Baruchel, S.1    Rowell, M.2
  • 4
    • 0003800704 scopus 로고    scopus 로고
    • National Cancer Institute of Canada: Cancer Statistics 2000, Toronto, Canada
    • Canadian Cancer Statistics. Canadian Cancer Statistics 2000 - Cancer in Children aged 0-19 years. National Cancer Institute of Canada: Cancer Statistics 2000, Toronto, Canada, 2000. Accessed June 22nd, 2005. Online: http://www.cancer.ca/stats2000.childe.htm.
    • (2000) Canadian Cancer Statistics 2000 - Cancer in Children Aged 0-19 Years
  • 5
    • 0033038974 scopus 로고    scopus 로고
    • The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine
    • Capizzi, R.L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin. Oncol. 1999, 26, 3-21.
    • (1999) Semin. Oncol. , vol.26 , pp. 3-21
    • Capizzi, R.L.1
  • 6
    • 0001828579 scopus 로고    scopus 로고
    • Late effects of childhood cancer and its treatment
    • Pizzo, P.A., Poplack, D.G., Eds. (Lippincott-Raven Publishers, Philadelphia)
    • Blatt, J.; Copeland, D.R.; Bleyer, W.A. Late effects of childhood cancer and its treatment. In Principles and Practice of Pediatric Oncology. Pizzo, P.A., Poplack, D.G., Eds. (Lippincott-Raven Publishers, Philadelphia, 1997), 1303-1329.
    • (1997) Principles and Practice of Pediatric Oncology , pp. 1303-1329
    • Blatt, J.1    Copeland, D.R.2    Bleyer, W.A.3
  • 7
    • 0037458325 scopus 로고    scopus 로고
    • Minimizing long-term tumor burden: The logic for metronomic chemotherapeutic dosing and its antiangiogenic basis
    • Hahnfeldt, P.; Folkman, J.; Hlatky, L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J. Theor. Biol. 2003, 220, 545-554.
    • (2003) J. Theor. Biol. , vol.220 , pp. 545-554
    • Hahnfeldt, P.1    Folkman, J.2    Hlatky, L.3
  • 8
    • 11444266441 scopus 로고    scopus 로고
    • Cancer anti-angiogenic therapy
    • Shimizu, K.;Oku, N. Cancer anti-angiogenic therapy. Biol. Pharm. Bull. 2004, 27, 599-605.
    • (2004) Biol. Pharm. Bull. , vol.27 , pp. 599-605
    • Shimizu, K.1    Oku, N.2
  • 9
    • 0035865363 scopus 로고    scopus 로고
    • Redefining the target: Chemotherapeutics as antiangiogenics
    • Miller, K.D.; Sweeney, C.J.; Sledge, G.W.; Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 2001, 19, 1195-1206.
    • (2001) J. Clin. Oncol. , vol.19 , pp. 1195-1206
    • Miller, K.D.1    Sweeney, C.J.2    Sledge Jr., G.W.3
  • 10
    • 0034161989 scopus 로고    scopus 로고
    • Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
    • Eberhard, A.; Kahlert, S.; Goede, V.; Hemmerlein, B.; Plate, K.H.; Augustin, H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000, 60, 1388-1393.
    • (2000) Cancer Res. , vol.60 , pp. 1388-1393
    • Eberhard, A.1    Kahlert, S.2    Goede, V.3    Hemmerlein, B.4    Plate, K.H.5    Augustin, H.G.6
  • 11
    • 0034087691 scopus 로고    scopus 로고
    • Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
    • Klement, G.; Baruchel, S.; Rak, J.; Man, S.; Clark, K.; Hicklin, D.J.; Bohlen, P.; Kerbel, R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 2000, 105, R15-R24.
    • (2000) J. Clin. Invest. , vol.105
    • Klement, G.1    Baruchel, S.2    Rak, J.3    Man, S.4    Clark, K.5    Hicklin, D.J.6    Bohlen, P.7    Kerbel, R.S.8
  • 12
    • 0034032882 scopus 로고    scopus 로고
    • Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
    • Browder, T.; Butterfield, C.E.; Kraling, B.M.; Shi, B.; Marshall, B.; O'Reilly, M.S.; Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000, 60, 1878-1886.
    • (2000) Cancer Res. , vol.60 , pp. 1878-1886
    • Browder, T.1    Butterfield, C.E.2    Kraling, B.M.3    Shi, B.4    Marshall, B.5    O'Reilly, M.S.6    Folkman, J.7
  • 13
    • 85013312416 scopus 로고
    • Tumor angiogenesis: Therapeutic implications
    • Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
    • (1971) N. Engl. J. Med. , vol.285 , pp. 1182-1186
    • Folkman, J.1
  • 14
    • 0025141337 scopus 로고
    • What is the evidence that tumors are angiogenesis dependent?
    • Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 1990, 82, 4-6.
    • (1990) J. Natl. Cancer Inst. , vol.82 , pp. 4-6
    • Folkman, J.1
  • 15
    • 2942615257 scopus 로고    scopus 로고
    • The anti-angiogenic basis of metronomic chemotherapy
    • Kerbel, R.S.; Kamen, B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4, 423-436.
    • (2004) Nat. Rev. Cancer , vol.4 , pp. 423-436
    • Kerbel, R.S.1    Kamen, B.A.2
  • 16
    • 0025717523 scopus 로고
    • Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
    • Kerbel, R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991, 13, 31-36.
    • (1991) Bioessays , vol.13 , pp. 31-36
    • Kerbel, R.S.1
  • 17
    • 16844381577 scopus 로고    scopus 로고
    • A new perspective on tumor endothelial cells: Unexpected chromosome and centrosome abnormalities
    • Hida, K.; Klagsbrun, M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res. 2005, 65, 2507-2510.
    • (2005) Cancer Res. , vol.65 , pp. 2507-2510
    • Hida, K.1    Klagsbrun, M.2
  • 18
    • 14644446018 scopus 로고    scopus 로고
    • A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
    • Pietras, K.; Hanahan, D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 2005, 23, 939-952.
    • (2005) J. Clin. Oncol. , vol.23 , pp. 939-952
    • Pietras, K.1    Hanahan, D.2
  • 19
    • 0034048358 scopus 로고    scopus 로고
    • Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
    • Hanahan, D.; Bergers, G.; Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 2000, 105, 1045-1047.
    • (2000) J. Clin. Invest. , vol.105 , pp. 1045-1047
    • Hanahan, D.1    Bergers, G.2    Bergsland, E.3
  • 20
    • 0028087294 scopus 로고
    • Cyclophosphamide-induced lung toxicity: Mechanism of endothelial cell injury
    • Kachel, D.L.; Martin, W.J. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J. Pharmacol. Exp. Ther. 1994, 268, 42-46.
    • (1994) J. Pharmacol. Exp. Ther. , vol.268 , pp. 42-46
    • Kachel, D.L.1    Martin, W.J.2
  • 21
    • 0026753046 scopus 로고
    • The effects of 5-fluorouracil and mitomycin C on the corneal endothelium
    • Nuyts, R.M.; Pels, E.; Greve, E. L. The effects of 5-fluorouracil and mitomycin C on the corneal endothelium. Curr. Eye. Res. 1992, 11, 565-570.
    • (1992) Curr. Eye. Res. , vol.11 , pp. 565-570
    • Nuyts, R.M.1    Pels, E.2    Greve, E.L.3
  • 22
  • 23
    • 0026444990 scopus 로고
    • Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay
    • Steiner, R. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. EXS 1992, 61, 449-454.
    • (1992) EXS , vol.61 , pp. 449-454
    • Steiner, R.1
  • 25
    • 0025793698 scopus 로고
    • Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism
    • Baguley, B.C.; Holdaway, K.M.; Thomsen, L.L.; Zhuang, L.; Zwi, L.J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer 1991, 27, 482-487.
    • (1991) Eur. J. Cancer , vol.27 , pp. 482-487
    • Baguley, B.C.1    Holdaway, K.M.2    Thomsen, L.L.3    Zhuang, L.4    Zwi, L.J.5
  • 27
    • 0031015504 scopus 로고    scopus 로고
    • Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol
    • Klauber, N.; Parangi, S.; Flynn, E.; Hamel, E.; D'Amato, R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997, 57, 81-86.
    • (1997) Cancer Res. , vol.57 , pp. 81-86
    • Klauber, N.1    Parangi, S.2    Flynn, E.3    Hamel, E.4    D'Amato, R.J.5
  • 28
    • 0032930199 scopus 로고    scopus 로고
    • Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer
    • Lau, D.H.; Xue, L.; Young, L.J.; Burke, P.A.; Cheung, A.T. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother. Radiopharm. 1999, 14, 31-36.
    • (1999) Cancer Biother. Radiopharm. , vol.14 , pp. 31-36
    • Lau, D.H.1    Xue, L.2    Young, L.J.3    Burke, P.A.4    Cheung, A.T.5
  • 29
    • 0033563116 scopus 로고    scopus 로고
    • Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process
    • Presta, M.; Rusnati, M.; Belleri, M.; Morbidelli, L.; Ziche, M.; Ribatti, D. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Res. 1999, 59, 2417-2424.
    • (1999) Cancer Res. , vol.59 , pp. 2417-2424
    • Presta, M.1    Rusnati, M.2    Belleri, M.3    Morbidelli, L.4    Ziche, M.5    Ribatti, D.6
  • 30
    • 0032956544 scopus 로고    scopus 로고
    • Antiangiogenic effects of camptothecin analogues 9-amino-20(S)- camptothecin, topotecan, and CPT-11 studied in the mouse cornea model
    • O'Leary, J.J.; Shapiro, R.L.; Ren, C.J.; Chuang, N.; Cohen, H.W.; Potmesil, M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin. Cancer Res. 1999, 5, 181-187.
    • (1999) Clin. Cancer Res. , vol.5 , pp. 181-187
    • O'Leary, J.J.1    Shapiro, R.L.2    Ren, C.J.3    Chuang, N.4    Cohen, H.W.5    Potmesil, M.6
  • 31
    • 0032532391 scopus 로고    scopus 로고
    • Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
    • Iyer, S.; Chaplin, D.J.; Rosenthal, D.S.; Boulares, A.M.; Li, L.Y.; Smulson, M.E. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 1998, 58, 4510-4514.
    • (1998) Cancer Res. , vol.58 , pp. 4510-4514
    • Iyer, S.1    Chaplin, D.J.2    Rosenthal, D.S.3    Boulares, A.M.4    Li, L.Y.5    Smulson, M.E.6
  • 32
    • 0032950870 scopus 로고    scopus 로고
    • Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
    • Chaplin, D.J.; Pettit, G.R.; Hill, S.A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 1999, 19, 189-195.
    • (1999) Anticancer Res. , vol.19 , pp. 189-195
    • Chaplin, D.J.1    Pettit, G.R.2    Hill, S.A.3
  • 33
    • 27644436870 scopus 로고    scopus 로고
    • The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
    • Shaked, Y.; Emmenegger, U.; Man, S.; Cervi, D.; Bertolini, F.; Ben David, Y.; Kerbel, R.S. The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. 2005, Blood.
    • (2005) Blood
    • Shaked, Y.1    Emmenegger, U.2    Man, S.3    Cervi, D.4    Bertolini, F.5    Ben David, Y.6    Kerbel, R.S.7
  • 34
    • 20944436688 scopus 로고    scopus 로고
    • Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity
    • Beaudry, P.; Force, J.; Naumov, G.N.; Wang, A.; Baker, C.H.; Ryan, A.; Soker, S.; Johnson, B.E.; Folkman, J.; Heymach, J.V. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005, 11, 3514-3522.
    • (2005) Clin Cancer Res. , vol.11 , pp. 3514-3522
    • Beaudry, P.1    Force, J.2    Naumov, G.N.3    Wang, A.4    Baker, C.H.5    Ryan, A.6    Soker, S.7    Johnson, B.E.8    Folkman, J.9    Heymach, J.V.10
  • 35
    • 0029092874 scopus 로고
    • Aspirin and reduced risk of esophageal carcinoma
    • Funkhouser, E.M.; Sharp, G.B. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995, 76, 1116-1119.
    • (1995) Cancer , vol.76 , pp. 1116-1119
    • Funkhouser, E.M.1    Sharp, G.B.2
  • 36
    • 0242331613 scopus 로고    scopus 로고
    • Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
    • U.S.A.
    • Bocci, G.; Francia, G.; Man, S.; Lawler, J.; Kerbel, R.S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 12917-12922.
    • (2003) Proc. Natl. Acad. Sci. , vol.100 , pp. 12917-12922
    • Bocci, G.1    Francia, G.2    Man, S.3    Lawler, J.4    Kerbel, R.S.5
  • 37
    • 0036225350 scopus 로고    scopus 로고
    • Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels
    • Colleoni, M.; Rocca, A.; Sandri, M.T.; Zorzino, L.; Masci, G.; Nole, F.; Peruzzotti, G.; Robertson, C.; Orlando, L.; Cinieri, S. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 2002, 13, 73-80.
    • (2002) Ann. Oncol. , vol.13 , pp. 73-80
    • Colleoni, M.1    Rocca, A.2    Sandri, M.T.3    Zorzino, L.4    Masci, G.5    Nole, F.6    Peruzzotti, G.7    Robertson, C.8    Orlando, L.9    Cinieri, S.10
  • 38
    • 0035214416 scopus 로고    scopus 로고
    • Metronomic scheduling: The future of chemotherapy?
    • Gasparini, G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001, 2, 733-740.
    • (2001) Lancet Oncol. , vol.2 , pp. 733-740
    • Gasparini, G.1
  • 41
    • 19644376976 scopus 로고    scopus 로고
    • Topotecan blocks hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells
    • Beppu, K.; Nakamura, K.; Linehan, W.M.; Rapisarda, A.; Thiele, C.J. Topotecan blocks hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res. 2005, 65, 4775-4781.
    • (2005) Cancer Res. , vol.65 , pp. 4775-4781
    • Beppu, K.1    Nakamura, K.2    Linehan, W.M.3    Rapisarda, A.4    Thiele, C.J.5
  • 44
    • 0042131613 scopus 로고    scopus 로고
    • Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis
    • Gately, S.; Kerbel, R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog. Exp. Tumor Res. 2003, 37, 179-192.
    • (2003) Prog. Exp. Tumor Res. , vol.37 , pp. 179-192
    • Gately, S.1    Kerbel, R.2
  • 45
    • 0036152447 scopus 로고    scopus 로고
    • Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts
    • Klement, G.; Huang, P.; Mayer, B.; Green, S.K.; Man, S.; Bohlen, P.; Hicklin, D.; Kerbel, R.S. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. 2002, 8, 221-232.
    • (2002) Clin. Cancer Res. , vol.8 , pp. 221-232
    • Klement, G.1    Huang, P.2    Mayer, B.3    Green, S.K.4    Man, S.5    Bohlen, P.6    Hicklin, D.7    Kerbel, R.S.8
  • 47
    • 0026486664 scopus 로고
    • Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
    • Teicher, B.A.; Sotomayor, E.A.; Huang, Z.D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 1992, 52, 6702-6704.
    • (1992) Cancer Res. , vol.52 , pp. 6702-6704
    • Teicher, B.A.1    Sotomayor, E.A.2    Huang, Z.D.3
  • 48
    • 0030920374 scopus 로고    scopus 로고
    • Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents
    • Kakeji, Y.; Teicher, B.A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997, 15, 39-48.
    • (1997) Invest New Drugs , vol.15 , pp. 39-48
    • Kakeji, Y.1    Teicher, B.A.2
  • 49
    • 12244265088 scopus 로고    scopus 로고
    • Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease
    • Cervi, D.; Klement, G.; Stempak, D.; Baruchel, S.; Koki, A.; Ben David, Y. Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease. Clin. Cancer Res. 2005, 11, 712-719.
    • (2005) Clin. Cancer Res. , vol.11 , pp. 712-719
    • Cervi, D.1    Klement, G.2    Stempak, D.3    Baruchel, S.4    Koki, A.5    Ben David, Y.6
  • 52
    • 0141958313 scopus 로고    scopus 로고
    • Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
    • Glode, L.M.; Barqawi, A.; Crighton, F.; Crawford, E.D.; Kerbel, R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003, 98, 1643-1648.
    • (2003) Cancer , vol.98 , pp. 1643-1648
    • Glode, L.M.1    Barqawi, A.2    Crighton, F.3    Crawford, E.D.4    Kerbel, R.5
  • 54
    • 2342436921 scopus 로고    scopus 로고
    • Anti-angiogenic chemotherapy in central nervous system tumors
    • Kieran, M.W. Anti-angiogenic chemotherapy in central nervous system tumors. Cancer Treat. Res. 2004, 117, 337-349.
    • (2004) Cancer Treat. Res. , vol.117 , pp. 337-349
    • Kieran, M.W.1
  • 55
    • 23844471332 scopus 로고    scopus 로고
    • A Multicenter Phase II study of Irinotecan(CPT), Cisplatin(CIS), and Bevacizumab(BEV) in patients with Unresectable or Metastatic Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma
    • Abstr.
    • Shah, M.A.; Ilson, D.; Ramanathan, R.K.; Levner, A.; D'Adamo, D.; Schwartz, L.; Casper, E.; Schwartz, G.K.; Kelsen, D.P. A Multicenter Phase II study of Irinotecan(CPT), Cisplatin(CIS), and Bevacizumab(BEV) in patients with Unresectable or Metastatic Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma. J. Clin. Oncol. 2005, 23, 4025 (Abstr.)
    • (2005) J. Clin. Oncol. , vol.23 , pp. 4025
    • Shah, M.A.1    Ilson, D.2    Ramanathan, R.K.3    Levner, A.4    D'Adamo, D.5    Schwartz, L.6    Casper, E.7    Schwartz, G.K.8    Kelsen, D.P.9
  • 56
    • 29444432612 scopus 로고    scopus 로고
    • Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial
    • Abstr.
    • Garcia. A.A.; Oza, A.M.; Hirte, H.; Fleming, G.; Tsao-Wei, D.; Roman, L.; Swenson, S.; Gandara, D.; Scudder, S.; Morgan, R. Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. J. Clin. Oncol. 2005, 23, 5000 (Abstr.)
    • (2005) J. Clin. Oncol. , vol.23 , pp. 5000
    • Garcia, A.A.1    Oza, A.M.2    Hirte, H.3    Fleming, G.4    Tsao-Wei, D.5    Roman, L.6    Swenson, S.7    Gandara, D.8    Scudder, S.9    Morgan, R.10
  • 57
    • 0002972502 scopus 로고    scopus 로고
    • Acute Lymphoblastic Leukemia
    • Pizzo, P.A., Poplack, D.G., Eds. (Lippincott-Raven Publishers, Philadelphia)
    • Margolin, J.F.; Poplack, D.G. Acute Lymphoblastic Leukemia. In Principles and Practice of Pediatric Oncology. Pizzo, P.A., Poplack, D.G., Eds. (Lippincott-Raven Publishers, Philadelphia, 1997), 409-461.
    • (1997) Principles and Practice of Pediatric Oncology , pp. 409-461
    • Margolin, J.F.1    Poplack, D.G.2
  • 60
    • 0036256785 scopus 로고    scopus 로고
    • Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors
    • Sterba, J.; Pavelka, Z.; Slampa, P. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 2002, 49, 117-120.
    • (2002) Neoplasma , vol.49 , pp. 117-120
    • Sterba, J.1    Pavelka, Z.2    Slampa, P.3
  • 65
    • 13944264243 scopus 로고    scopus 로고
    • Don't throw out the baby with the bathwater!
    • Kamen, B.; Kieran, M. Don't throw out the baby with the bathwater! J. Pediatr. Hematol. Oncol. 2005, 27, 59-60.
    • (2005) J. Pediatr. Hematol. Oncol. , vol.27 , pp. 59-60
    • Kamen, B.1    Kieran, M.2
  • 68
    • 1542267857 scopus 로고    scopus 로고
    • Oral etoposide for recurrent/progressive sarcomas of childhood
    • Kebudi, R.; Gorgun, O.; Ayan, I. Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatr. Blood Cancer 2004, 42, 320-324.
    • (2004) Pediatr. Blood Cancer , vol.42 , pp. 320-324
    • Kebudi, R.1    Gorgun, O.2    Ayan, I.3
  • 69
    • 0034796595 scopus 로고    scopus 로고
    • Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
    • Jain, R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7, 987-989.
    • (2001) Nat. Med. , vol.7 , pp. 987-989
    • Jain, R.K.1
  • 70
    • 12344296657 scopus 로고    scopus 로고
    • A surrogate marker to monitor angiogenesis at last
    • Schneider, M.; Tjwa, M.; Carmeliet, P. A surrogate marker to monitor angiogenesis at last. Cancer Cell 2005, 7, 3-4.
    • (2005) Cancer Cell , vol.7 , pp. 3-4
    • Schneider, M.1    Tjwa, M.2    Carmeliet, P.3
  • 71
    • 19944432454 scopus 로고    scopus 로고
    • Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis
    • Shaked, Y.; Bertolini, F.; Man, S.; Rogers, M.S.; Cervi, D.; Foutz, T.; Rawn, K.; Voskas, D.; Dumont, D.J.; Ben David, Y. et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005, 7, 101-111.
    • (2005) Cancer Cell , vol.7 , pp. 101-111
    • Shaked, Y.1    Bertolini, F.2    Man, S.3    Rogers, M.S.4    Cervi, D.5    Foutz, T.6    Rawn, K.7    Voskas, D.8    Dumont, D.J.9    Ben David, Y.10
  • 72
    • 18944379083 scopus 로고    scopus 로고
    • Can a rational design for metronomic chemotherapy dosing be devised?
    • Maraveyas, A.; Lam, T.; Hetherington, J.W.; Greenman, J. Can a rational design for metronomic chemotherapy dosing be devised? Br. J. Cancer 2005, 92, 1588-1590.
    • (2005) Br. J. Cancer , vol.92 , pp. 1588-1590
    • Maraveyas, A.1    Lam, T.2    Hetherington, J.W.3    Greenman, J.4
  • 73
    • 0002466429 scopus 로고
    • Drug Therapeutics in the Infant and Child
    • Yaffe, S.J., Aranda, J.V., Eds. (Saunders, Philadelphia)
    • Kauffman, R.E. Drug Therapeutics in the Infant and Child. In Pediatric Pharmacology: Therapeutic Principles in Practice. Yaffe, S.J., Aranda, J.V., Eds. (Saunders, Philadelphia, 1992), 212-219.
    • (1992) Pediatric Pharmacology: Therapeutic Principles in Practice , pp. 212-219
    • Kauffman, R.E.1
  • 74
    • 0028567081 scopus 로고
    • Pharmacokinetic variability in the adolescent: Implications of body size and organ function for dosage regimen design
    • Rodman, J.H. Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design. J. Adolesc. Health 1994, 15, 654-662.
    • (1994) J. Adolesc. Health , vol.15 , pp. 654-662
    • Rodman, J.H.1
  • 75
    • 0024835315 scopus 로고
    • Clinical pharmacokinetics in infants and children. A reappraisal
    • Kearns, G.L.; Reed, M.D. Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinet. 1989, 17 Suppl 1, 29-67.
    • (1989) Clin. Pharmacokinet. , vol.17 , Issue.1 SUPPL. , pp. 29-67
    • Kearns, G.L.1    Reed, M.D.2
  • 76
    • 0034033851 scopus 로고    scopus 로고
    • Human cytochrome P450 maximal activities in pediatric versus adult liver
    • Blanco, J.G.; Harrison, P.L.; Evans, W.E.; Relling, M.V. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos. 2000, 28, 379-382.
    • (2000) Drug Metab Dispos. , vol.28 , pp. 379-382
    • Blanco, J.G.1    Harrison, P.L.2    Evans, W.E.3    Relling, M.V.4
  • 77
    • 0013332243 scopus 로고
    • Pharmacokinetics in Children
    • Azarnoff, D.L., Ed. (Churchill Livingstone, New York)
    • Boreus, L.O. Pharmacokinetics in Children. In Principles of Pediatric Pharmacology. Azarnoff, D.L., Ed. (Churchill Livingstone, New York, 1982), 135-175.
    • (1982) Principles of Pediatric Pharmacology , pp. 135-175
    • Boreus, L.O.1
  • 78
    • 0034092011 scopus 로고    scopus 로고
    • Tumor angiogenesis: Past, present and the near future
    • Kerbel, R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000, 21, 505-515.
    • (2000) Carcinogenesis , vol.21 , pp. 505-515
    • Kerbel, R.S.1
  • 79
    • 0035253586 scopus 로고    scopus 로고
    • Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
    • Margolin, K.; Gordon, M.S.; Holmgren, E.; Gaudreault, J.; Novotny, W.; Fyfe, G.; Adelman, D.; Stalter, S.; Breed, J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 2001, 19, 851-856.
    • (2001) J. Clin. Oncol. , vol.19 , pp. 851-856
    • Margolin, K.1    Gordon, M.S.2    Holmgren, E.3    Gaudreault, J.4    Novotny, W.5    Fyfe, G.6    Adelman, D.7    Stalter, S.8    Breed, J.9
  • 81
    • 0034000338 scopus 로고    scopus 로고
    • Prognostic value of vascular endothelial growth factor in breast cancer
    • Gasparini, G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000, 5 Suppl 1, 37-44.
    • (2000) Oncologist , vol.5 , Issue.1 SUPPL. , pp. 37-44
    • Gasparini, G.1
  • 82
    • 0031409282 scopus 로고    scopus 로고
    • Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    • Dosquet, C.; Coudert, M.C.; Lepage, E.; Cabane, J.; Richard, F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin. Cancer Res. 1997, 3, 2451-2458.
    • (1997) Clin. Cancer Res. , vol.3 , pp. 2451-2458
    • Dosquet, C.1    Coudert, M.C.2    Lepage, E.3    Cabane, J.4    Richard, F.5
  • 83
    • 0030997316 scopus 로고    scopus 로고
    • Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
    • Dirix, L.Y.; Vermeulen, P.B.; Pawinski, A.; Prove, A.; Benoy, I.; De Pooter, C.; Martin, M.; van Oosterom, A.T. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br. J. Cancer 1997, 76, 238-243.
    • (1997) Br. J. Cancer , vol.76 , pp. 238-243
    • Dirix, L.Y.1    Vermeulen, P.B.2    Pawinski, A.3    Prove, A.4    Benoy, I.5    De Pooter, C.6    Martin, M.7    Van Oosterom, A.T.8
  • 85
    • 0035865450 scopus 로고    scopus 로고
    • Clinical implications of circulating angiogenic factors in cancer patients
    • Poon, R.T.; Fan, S.T.; Wong, J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 2001, 19, 1207-1225.
    • (2001) J. Clin. Oncol. , vol.19 , pp. 1207-1225
    • Poon, R.T.1    Fan, S.T.2    Wong, J.3
  • 89
    • 0028916239 scopus 로고
    • Diagnostic and prognostic role of basic fibroblast growth factor in Wilms' tumor patients
    • Lin, R.Y.; Argenta, P.A.; Sullivan, K.M.; Adzick, N.S. Diagnostic and prognostic role of basic fibroblast growth factor in Wilms' tumor patients. Clin Cancer Res. 1995, 1, 327-331.
    • (1995) Clin Cancer Res. , vol.1 , pp. 327-331
    • Lin, R.Y.1    Argenta, P.A.2    Sullivan, K.M.3    Adzick, N.S.4
  • 90
    • 0036168594 scopus 로고    scopus 로고
    • Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels
    • Jeha, S.; Smith, F.O.; Estey, E.; Shen, Y.; Liu, D.; Manshouri, T.; Albitar, M. Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels. Leuk. Res. 2002, 26, 399-402.
    • (2002) Leuk. Res. , vol.26 , pp. 399-402
    • Jeha, S.1    Smith, F.O.2    Estey, E.3    Shen, Y.4    Liu, D.5    Manshouri, T.6    Albitar, M.7
  • 91
    • 0036718433 scopus 로고    scopus 로고
    • Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients
    • de Bont, E.S.; Fidler, V.; Meeuwsen, T.; Scherpen, F.; Hahlen, K.; Kamps, W.A. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin. Cancer Res. 2002, 8, 2856-2861.
    • (2002) Clin. Cancer Res. , vol.8 , pp. 2856-2861
    • De Bont, E.S.1    Fidler, V.2    Meeuwsen, T.3    Scherpen, F.4    Hahlen, K.5    Kamps, W.A.6
  • 92
    • 0034905950 scopus 로고    scopus 로고
    • Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
    • Tabone, M.D.; Landman-Parker, J.; Arcil, B.; Coudert, M.C.; Gerota, I.; Benbunan, M.; Leverger, G.; Dosquet, C. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? Clin. Cancer Res. 2001, 7, 538-543.
    • (2001) Clin. Cancer Res. , vol.7 , pp. 538-543
    • Tabone, M.D.1    Landman-Parker, J.2    Arcil, B.3    Coudert, M.C.4    Gerota, I.5    Benbunan, M.6    Leverger, G.7    Dosquet, C.8
  • 94
    • 1642368865 scopus 로고    scopus 로고
    • Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression
    • Hamano, Y.; Sugimoto, H.; Soubasakos, M.A.; Kieran, M.; Olsen, B.R.; Lawler, J.; Sudhakar, A.; Kalluri, R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004, 64, 1570-1574.
    • (2004) Cancer Res. , vol.64 , pp. 1570-1574
    • Hamano, Y.1    Sugimoto, H.2    Soubasakos, M.A.3    Kieran, M.4    Olsen, B.R.5    Lawler, J.6    Sudhakar, A.7    Kalluri, R.8
  • 95
    • 4644271546 scopus 로고    scopus 로고
    • Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies
    • Bocci, G.; Man, S.; Green, S.K.; Francia, G.; Ebos, J.M.; du Manoir, J.M.; Weinerman, A.; Emmenegger, U.; Ma, L.; Thorpe, P. et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 2004, 64, 6616-6625.
    • (2004) Cancer Res. , vol.64 , pp. 6616-6625
    • Bocci, G.1    Man, S.2    Green, S.K.3    Francia, G.4    Ebos, J.M.5    Du Manoir, J.M.6    Weinerman, A.7    Emmenegger, U.8    Ma, L.9    Thorpe, P.10
  • 97
    • 0041589524 scopus 로고    scopus 로고
    • Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
    • Bertolini, F.; Paul, S.; Mancuso, P.; Monestiroli, S.; Gobbi, A.; Shaked, Y.; Kerbel, R.S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003, 63, 4342-4346.
    • (2003) Cancer Res. , vol.63 , pp. 4342-4346
    • Bertolini, F.1    Paul, S.2    Mancuso, P.3    Monestiroli, S.4    Gobbi, A.5    Shaked, Y.6    Kerbel, R.S.7
  • 98
    • 0033529618 scopus 로고    scopus 로고
    • Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
    • Asahara, T.; Masuda, H.; Takahashi, T.; Kalka, C.; Pastore, C.; Silver, M.; Kearne, M.; Magner, M.; Isner, J.M. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 1999, 85, 221-228.
    • (1999) Circ. Res. , vol.85 , pp. 221-228
    • Asahara, T.1    Masuda, H.2    Takahashi, T.3    Kalka, C.4    Pastore, C.5    Silver, M.6    Kearne, M.7    Magner, M.8    Isner, J.M.9
  • 99
    • 0033565540 scopus 로고    scopus 로고
    • VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
    • Asahara, T.; Takahashi, T.; Masuda, H.; Kalka, C.; Chen, D.; Iwaguro, H.; Inai, Y.; Silver, M.; Isner, J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999, 18, 3964-3972.
    • (1999) EMBO J. , vol.18 , pp. 3964-3972
    • Asahara, T.1    Takahashi, T.2    Masuda, H.3    Kalka, C.4    Chen, D.5    Iwaguro, H.6    Inai, Y.7    Silver, M.8    Isner, J.M.9
  • 100
    • 0036831559 scopus 로고    scopus 로고
    • Vascular and haematopoietic stem cells: Novel targets for antiangiogenesis therapy?
    • Rafii, S.; Lyden, D.; Benezra, R.; Hattori, K.; Heissig, B. Vascular and haematopoietic stem cells: novel targets for antiangiogenesis therapy? Nat. Rev. Cancer 2002, 2, 826-835.
    • (2002) Nat. Rev. Cancer , vol.2 , pp. 826-835
    • Rafii, S.1    Lyden, D.2    Benezra, R.3    Hattori, K.4    Heissig, B.5
  • 101
    • 0035160312 scopus 로고    scopus 로고
    • Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
    • Lyden, D.; Hattori, K.; Dias, S.; Costa, C.; Blaikie, P.; Butros, L.; Chadburn, A.; Heissig, B.; Marks, W.; Witte, L. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7, 1194-1201.
    • (2001) Nat. Med. , vol.7 , pp. 1194-1201
    • Lyden, D.1    Hattori, K.2    Dias, S.3    Costa, C.4    Blaikie, P.5    Butros, L.6    Chadburn, A.7    Heissig, B.8    Marks, W.9    Witte, L.10
  • 102
    • 0142258071 scopus 로고    scopus 로고
    • Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors
    • Sikder, H.; Huso, D.L.; Zhang, H.; Wang, B.; Ryu, B.; Hwang, S.T.; Powell, J.D.; Alani, R.M. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003, 4, 291-299.
    • (2003) Cancer Cell , vol.4 , pp. 291-299
    • Sikder, H.1    Huso, D.L.2    Zhang, H.3    Wang, B.4    Ryu, B.5    Hwang, S.T.6    Powell, J.D.7    Alani, R.M.8
  • 103
    • 0003138605 scopus 로고    scopus 로고
    • Conventional and high-speed intravital multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-endothelial interactions
    • Padera, T.P.; Stoll, B.R.; So, P.T.; Jain, R.K. Conventional and high-speed intravital multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-endothelial interactions. Mol. Imaging 2002, 1, 9-15.
    • (2002) Mol. Imaging , vol.1 , pp. 9-15
    • Padera, T.P.1    Stoll, B.R.2    So, P.T.3    Jain, R.K.4
  • 104
    • 0346365369 scopus 로고    scopus 로고
    • Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells
    • Schuch, G.; Heymach, J.V.; Nomi, M.; Machluf, M.; Force, J.; Atala, A.; Eder, J.P.; Jr.; Folkman, J.; Soker, S. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res. 2003, 63, 8345-8350.
    • (2003) Cancer Res. , vol.63 , pp. 8345-8350
    • Schuch, G.1    Heymach, J.V.2    Nomi, M.3    Machluf, M.4    Force, J.5    Atala, A.6    Eder Jr., J.P.7    Folkman, J.8    Soker, S.9
  • 106
    • 0035383784 scopus 로고    scopus 로고
    • Resting and activated endothelial cells are increased in the peripheral blood of cancer patients
    • Mancuso, P.; Burlini, A.; Pruneri, G.; Goldhirsch, A.; Martinelli, G.; Bertolini, F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001, 97, 3658-3661.
    • (2001) Blood , vol.97 , pp. 3658-3661
    • Mancuso, P.1    Burlini, A.2    Pruneri, G.3    Goldhirsch, A.4    Martinelli, G.5    Bertolini, F.6
  • 107
    • 0035360833 scopus 로고    scopus 로고
    • Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma
    • Monestiroli, S.; Mancuso, P.; Burlini, A.; Pruneri, G.; Dell'Agnola, C.; Gobbi, A.; Martinelli, G.; Bertolini, F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 2001, 61, 4341-4344.
    • (2001) Cancer Res. , vol.61 , pp. 4341-4344
    • Monestiroli, S.1    Mancuso, P.2    Burlini, A.3    Pruneri, G.4    Dell'Agnola, C.5    Gobbi, A.6    Martinelli, G.7    Bertolini, F.8
  • 110
    • 0033989026 scopus 로고    scopus 로고
    • Origins of circulating endothelial cells and endothelial outgrowth from blood
    • Lin, Y.; Weisdorf, D.J.; Solovey, A.; Hebbel, R.P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 2000, 105, 71-77.
    • (2000) J. Clin. Invest. , vol.105 , pp. 71-77
    • Lin, Y.1    Weisdorf, D.J.2    Solovey, A.3    Hebbel, R.P.4
  • 112
    • 85047686759 scopus 로고    scopus 로고
    • Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma
    • Sussman, L.K.; Upalakalin, J.N.; Roberts, M.J.; Kocher, O.; Benjamin, L.E. Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma. Cancer Biol. Ther. 2003, 2, 255-256.
    • (2003) Cancer Biol. Ther. , vol.2 , pp. 255-256
    • Sussman, L.K.1    Upalakalin, J.N.2    Roberts, M.J.3    Kocher, O.4    Benjamin, L.E.5
  • 113
    • 0942277099 scopus 로고    scopus 로고
    • Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients
    • Beerepoot, L.V.; Mehra, N.; Vermaat, J.S.; Zonnenberg, B.A.; Gebbink, M.F.; Voest, E.E. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann. Oncol. 2004, 15, 139-145.
    • (2004) Ann. Oncol. , vol.15 , pp. 139-145
    • Beerepoot, L.V.1    Mehra, N.2    Vermaat, J.S.3    Zonnenberg, B.A.4    Gebbink, M.F.5    Voest, E.E.6
  • 114
    • 3042523515 scopus 로고    scopus 로고
    • Assessing tumor angiogenesis: Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells
    • Rabascio, C.; Muratori, E.; Mancuso, P.; Calleri, A.; Raia, V.; Foutz, T.; Cinieri, S.; Veronesi, G.; Pruneri, G.; Lampertico, P. et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res. 2004, 64, 4373-4377.
    • (2004) Cancer Res. , vol.64 , pp. 4373-4377
    • Rabascio, C.1    Muratori, E.2    Mancuso, P.3    Calleri, A.4    Raia, V.5    Foutz, T.6    Cinieri, S.7    Veronesi, G.8    Pruneri, G.9    Lampertico, P.10
  • 115
    • 0033986273 scopus 로고    scopus 로고
    • Circulating endothelial precursors: Mystery, reality, and promise
    • Rafii, S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 2000, 105, 17-19.
    • (2000) J. Clin. Invest. , vol.105 , pp. 17-19
    • Rafii, S.1
  • 116
    • 0035160312 scopus 로고    scopus 로고
    • Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
    • Lyden, D.; Hattori, K.; Dias, S.; Costa, C.; Blaikie, P.; Butros, L.; Chadburn, A.; Heissig, B.; Marks, W.; Witte, L. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7, 1194-1201.
    • (2001) Nat. Med. , vol.7 , pp. 1194-1201
    • Lyden, D.1    Hattori, K.2    Dias, S.3    Costa, C.4    Blaikie, P.5    Butros, L.6    Chadburn, A.7    Heissig, B.8    Marks, W.9    Witte, L.10
  • 117
    • 0036848878 scopus 로고    scopus 로고
    • Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo
    • Bolontrade, M.F.; Zhou, R.R.; Kleinerman, E.S. Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo. Clin. Cancer Res. 2002, 8, 3622-3627.
    • (2002) Clin. Cancer Res. , vol.8 , pp. 3622-3627
    • Bolontrade, M.F.1    Zhou, R.R.2    Kleinerman, E.S.3
  • 119
    • 0037967272 scopus 로고    scopus 로고
    • Tumorigenesis and the angiogenic switch
    • Bergers, G.; Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3, 401-410.
    • (2003) Nat. Rev. Cancer , vol.3 , pp. 401-410
    • Bergers, G.1    Benjamin, L.E.2
  • 120
    • 23844483271 scopus 로고    scopus 로고
    • Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation
    • Bocci, G.; Tuccori, M.; Emmenegger, U.; Liguori, V.; Falcone, A.; Kerbel, R.S.; Del Tacca, M. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann. Oncol. 2005.
    • (2005) Ann. Oncol.
    • Bocci, G.1    Tuccori, M.2    Emmenegger, U.3    Liguori, V.4    Falcone, A.5    Kerbel, R.S.6    Del Tacca, M.7
  • 122
    • 23944470359 scopus 로고    scopus 로고
    • Prospects for therapeutic inhibition of neuroblastoma angiogenesis
    • Shusterman, S.; Maris, J.M. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett. 2005.
    • (2005) Cancer Lett.
    • Shusterman, S.1    Maris, J.M.2
  • 123
    • 2542539735 scopus 로고    scopus 로고
    • A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens
    • Emmenegger, U.; Man, S.; Shaked, Y.; Francia, G.; Wong, J.W.; Hicklin, D.J.; Kerbel, R.S. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. 2004, 64, 3994-4000.
    • (2004) Cancer Res. , vol.64 , pp. 3994-4000
    • Emmenegger, U.1    Man, S.2    Shaked, Y.3    Francia, G.4    Wong, J.W.5    Hicklin, D.J.6    Kerbel, R.S.7
  • 125
    • 14944377007 scopus 로고    scopus 로고
    • Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma
    • Su, Y.W.; Chang, M.C.; Chiang, M.F.; Hsieh, R.K. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J. Neurooncol. 2005, 71, 315-318.
    • (2005) J. Neurooncol. , vol.71 , pp. 315-318
    • Su, Y.W.1    Chang, M.C.2    Chiang, M.F.3    Hsieh, R.K.4
  • 126
    • 0038376001 scopus 로고    scopus 로고
    • Imaging of angiogenesis: From microscope to clinic
    • McDonald, D.M.; Choyke, P.L. Imaging of angiogenesis: from microscope to clinic. Nat. Med. 2003, 9, 713-725.
    • (2003) Nat. Med. , vol.9 , pp. 713-725
    • McDonald, D.M.1    Choyke, P.L.2
  • 128
    • 0347615101 scopus 로고    scopus 로고
    • Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies
    • Morgan, B.; Thomas, A.L.; Drevs, J.; Hennig, J.; Buchert, M.; Jivan, A.; Horsfield, M.A.; Mross, K.; Ball, H.A.; Lee, L. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 2003, 21, 3955-3964.
    • (2003) J. Clin. Oncol. , vol.21 , pp. 3955-3964
    • Morgan, B.1    Thomas, A.L.2    Drevs, J.3    Hennig, J.4    Buchert, M.5    Jivan, A.6    Horsfield, M.A.7    Mross, K.8    Ball, H.A.9    Lee, L.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.